Natera’s ctDNA MRD Test Powers ALPHA3 Trial with Day-45 April Readout
Allogene’s ALPHA3 frontline trial integrates Natera’s Foresight ctDNA MRD assay to detect minimal residual disease in LBCL patients in remission, randomizing 12 MRD-positive patients per arm to observation or cema-cel with initial day-45 clearance results due in April. The study deploys Natera’s assay across 50% community sites using outpatient workflows.
1. Foresight Acquisition Strengthens Natera’s Pipeline
Natera’s acquisition of Foresight Diagnostics added an ultrasensitive PCR-based ctDNA MRD assay to its portfolio, enabling highly sensitive detection of minimal residual disease in lymphoma patients. This platform avoids radiation exposure and leverages blood-based testing to identify residual tumor not visible on imaging.
2. Integration in ALPHA3 Trial
Allogene’s ALPHA3 trial uses Natera’s Foresight assay to screen frontline remission LBCL patients for MRD positivity, randomizing an expected 12 patients per arm to standard observation or cema-cel treatment. Initial data in April will compare MRD clearance rates at day 45 and report preliminary safety and outpatient administration outcomes.
3. Market and Revenue Implications
The trial involves MRD testing at approximately half of community sites, reflecting broader outpatient adoption potential for Natera’s assay. With an expected 20% MRD positivity rate and a futility bar targeting a 25–30% clearance delta, successful readouts could drive commercial uptake and revenue growth from both trial services and diagnostic sales.